8 August 2018 - In a move to increase drug price transparency, CVS Health said its retained share of rebates negotiated with drug makers comes to 2%, which will translate this year to 3% of the company’s annual earnings per share or about $300 million.

The disclosure by CVS during the company’s second-quarter earnings call is a first to detail what the pharmacy chain’s Caremark PBM keeps as profit. The PBM’s share of rebates, which is the portion of the drug returned by the seller to the buyer, has turned into a nationwide controversy and drawn the attention of the Trump administration and Congress.

But CVS retained share of rebates in 2018 amounts to 3% of the company's adjusted earnings-per-share , the company disclosed during its second quarter earnings call Wednesday morning.

Read Forbes article